DSCSA – Guidance documents provided by the US Food and Drug Administration

CHUCK SAILER | July 9, 2017

article image
The US Food and Drug Administration (FDA) has published guidance documents to help MAHs and CMOs navigate the Drug Supply Chain Security Act (DSCSA). The first major DSCSA serialization deadline is drawing near. Indeed, as of November 2017, all prescription medicines destined for the American market will have to be serialized.

Spotlight

Embleema

Imagine a world in which everyone can contribute to medical research and create safer, less expensive and faster new treatments. Imagine a tamper-proof, holistic, longitudinal and patient-centric worldwide health record interfacing with patients, physicians, care centers, health authorities and the pharmaceutical industry.

OTHER ARTICLES

Artificial intelligence in pharma: utilising a valuable resource

Article | March 11, 2020

The pharmaceutical industry is set to greatly benefit from the use of artificial intelligence (AI), due to its wide range of applications. Sydney Tierney discusses how machine learning can enhance marketing, manufacturing and drug trials. Artificial intelligence (AI) can be applied to nearly every aspect of the pharmaceutical and healthcare industry, to enhance data processing. Adopting the technology will reveal the astonishing potential of the healthcare sector, with success rates flying higher than ever before – especially in the research and development of crucial, life-changing drugs.

Read More

Do Clinical Trial Delays Mean Trouble for Pharmaceutical Stocks?

Article | April 1, 2020

Pharmaceutical stocks have been somewhat of a safe haven for investors as the coronavirus outbreak spread from China to the rest of the world. But as the pandemic deepened, now resulting in more than 782,000 cases worldwide, even these "safer" companies are beginning to feel the effects. The U.S. is now the coronavirus epicenter, with the most cases -- more than 161,000 as of today. Initial concerns for drugmakers had to do with the supply of active pharmaceutical ingredients, which often come from China. The worry was that pharmaceutical companies wouldn't be able to produce enough of their drugs for patients.

Read More

Enabling Active Pharma Ingredients for Batch Balancing and Integration to SAP EWM

Article | April 6, 2020

Batch and its Classification system are two most potent weapons used in Chemical, Pharma or Medical life science industry to record the potency of a batch or technically called as Active Pharma Ingredients(API). These material consist of one or more active ingredients, concentrates, carrier materials, or impurities, and so on. The potency of the active ingredients varies from batch to batch. The active ingredient is the substance of greatest interest in the bill of materials, the proportion of which may vary from batch to batch. Therefore, during creation of a process order, the system must be able to select and adjust the batches needed to obtain the required amount of active ingredient. Take an example of a drug hydroxychloroquine which is used as potent weapon to fight COVID-19. This drug is manufactured by using API, however, the Potency of this API material vary from batch to batch. To map this kind of requirement in SAP ERP, SAP calls it as Material Quantity Calculation.

Read More

Advance Your Pharma Supply Chain Planning during a Pandemic

Article | March 20, 2020

One predominant and common element within our pharmaceutical industry, is our devotions to patients. Within supply chain there is always a focus on ensuring the right product is delivered to the right place at the right time in order to ensure patient safety and the continuity of medicinal supplies. With the spread of COVID-19 across 117 countries and counting, every supply chain needs to evaluate their global footprint and develop contingency plans within their end to end operations.

Read More

Spotlight

Embleema

Imagine a world in which everyone can contribute to medical research and create safer, less expensive and faster new treatments. Imagine a tamper-proof, holistic, longitudinal and patient-centric worldwide health record interfacing with patients, physicians, care centers, health authorities and the pharmaceutical industry.

Events